New York Times
GlaxoSmithKline target adopts 'poison pill'
By David Sell Human Genome Sciences Inc. filed a plan with regulators Thursday to try to block GlaxoSmithKline PLC's $2.6 billion takeover offer for the Maryland-based pharmaceutical company. The shareholder-rights plan — a corporate tactic often …
Glaxo undeterred by Human Genome 'poison pill'
Human Genome adopts 'poison pill' measure